Skip to main content
SpringerLink
Log in

Are immune checkpoint inhibitors cost effective in NSCLC?

  • Review
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Ding H, et al. Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review. PLOS One : 2 Sep 2020. Available from: URL: https://doi.org/10.1371/journal.pone.0238536

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Are immune checkpoint inhibitors cost effective in NSCLC?. PharmacoEcon Outcomes News 862, 2 (2020). https://doi.org/10.1007/s40274-020-7120-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-7120-y

Search

Navigation